CompletedPhase 4NCT02274259

Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen

Studying Central retinal vein occlusion

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Anders Kvanta
Principal Investigator
Sofie Westman
Study coordinator
Intervention
Aflibercept(drug)
Enrollment
40 enrolled
Eligibility
18 years · All sexes
Timeline
20142016

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02274259 on ClinicalTrials.gov

Other trials for Central retinal vein occlusion

Additional recruiting or active studies for the same condition.

See all trials for Central retinal vein occlusion

← Back to all trials